HIV/HCV co-infection: The magnitude of the problem

Journal of Biological Regulators and Homeostatic Agents

Volumn 17, Issue 2, 2003, Pages 138-143

  Balestra, E ^a   Aquaro, S ^a   Perno, Carlo Federico ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Coinfection; HCV; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; PROTEINASE INHIBITOR;

ARTICLE; DISEASE COURSE; DRUG USE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; LIFE CYCLE; LIVER DISEASE; MORBIDITY; MORTALITY; NONHUMAN; PERSISTENT VIRUS INFECTION; SUPERINFECTION; SURVIVAL RATE; VIRUS TRANSMISSION;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0141504930     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 2001; 285: 1308-15.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
3. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-7.
4. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240-7.
5. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
6. Poles MA, Dieterich DT. Hepatitis C virus/human immunodeficiency virus coinfection: Clinical management issues. Clin Infect Dis 2000; 31: 154-61.
7. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-7.
8. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines on the management of occupational exposures to HBV, HCV, and HIV and recommendations for post-exposure prophylaxis. MMWR Morb Mortal Wkly Rep 2001; 50: 1-67.
9. Gray RH, Wawer MJ, Brookmeyer R, et al. Rakai Project Team. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357: 1149-53.
10. Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet. 1995; 345: 289-91.
11. Gibb DM, Goodall RL, Dunn DT, et al. Mother-to-child transmission of hepatitis C virus: Evidence for preventable peripartum transmission. Lancet 2000; 356: 904-7.
12. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998; 177: 1480-8.
13. Hershow RC, Riester KA, Lew J, et al. Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. Women and Infants Transmission Study. J Infect Dis 1997; 176: 414-20.
14. Pollard RB. Analogy of human immunodeficiency virus to hepatitis C virus: the human immunodeficiency model. Am J Med 1999; 107 (Suppl.): S41-4.
15. Ramratnam B, Bonhoeffer S, Binley J, et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999; 354: 1782-5.
16. Ji J, Hoffmann JS, Loeb L. Mutagenicity and pausing of HIV reverse transcriptase during HIV plus-strand DNA synthesis. Nucleic Acids Res 1994; 22: 47-52.
17. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002; 76: 8505-17.
18. Pawlotsky JM. Hepatitis C virus genetic variability: Pathogenic and clinical implications. Clin Liver Dis 2003; 7: 45-66.
19. Ray SC, Mao Q, Lanford LE, et al. Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. J Virol 2000; 74: 3058-66.
20. Mao Q, Ray SC, Laeyendecker O, et al. Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies. J Virol 2001; 75: 3259-67.
21. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-71.
22. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-41.
23. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000; 32: 818-23.
24. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-83.
25. Villano SA, Vlahov D, Nelson K.E, Chon S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 908-14.
26. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47: 1-40.
27. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.
28. Thomas DL, Astemborski J, Vlahov D, et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000; 181: 844-51.
29. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183: 1112-5.
30. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 179: 1254-8.
31. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001; 33: 562-9.
32. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997; 350: 1425-31.
33. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA 2000; 284: 450-6.
34. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 1995; 172: 1503-8.
35. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
36. Greub G, Ledergerber B, Battegay M, et al, for the Swiss HIV Cohort Study. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study. Lancet 2000; 356: 1800-5.
37. Tebaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due immunodeficiency virus infection in the era of highly active antiretroviral thrapy. Clin Infect Dis 2003; 36: 363-7.
38. Puoti M, Torti C, Ripamonti D, et al. HIV-HCV Co-Infection Study Group. Severe hepatotoxicity during combination antiretroviral treatment: Incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003; 32: 259-67.